Martin Eisele succeeded Birgit Leibfritz as a member of the Chemoform AG Management Board on 1 April 2023.
After almost twelve years with the company and successful work as Board Member for Finance, IT and Human Resources, Birgit Leibfritz took her well-deserved retirement on 31 March 2023. In addition to all her professional skills, her human and hands-on manner made her an ever-appreciated point of contact for employees, customers and partners. “I would like to express my sincere thanks to Birgit Leibfritz for her outstanding work and commitment over the years. During our time together, a company with sales of 40 million euros has become a group of companies with sales of more than 350 million euros”, says CEO Cedrik Mayer-Klenk with regard to the change in leadership. “At the same time, I am glad and grateful that we were able to find a suitable and competent successor in Martin Eisele”.
As a tax advisor and auditor, the new CFO Martin Eisele can look back on a long career in management positions and brings with him extensive experience in finance and controlling. Following his involvement as a senior manager at the auditing company Ernst & Young, where he was responsible for auditing an M-DAX company, among other things, he managed a single family office for eight years from 2012 and was self-employed with his own office.
With the appointment of Martin Eisele to the Management Board, a new chapter begins for CF group. The focus here is on consolidating the corporate and group concept in order to successfully develop into an internationally sustainable, capital market-oriented group of companies. Further elements are the integration and consolidation of the acquisitions made and those to be made in the future.